Jordana B Cohen1, Debbie L Cohen2, Daniel S Herman2, John T Leppert3, James Brian Byrd4, Vivek Bhalla5. 1. Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania (J.B.C.). 2. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania (D.L.C., D.S.H.). 3. Stanford University School of Medicine, Stanford, California, and Veterans Affairs Palo Alto Health Care System, Palo Alto, California (J.T.L.). 4. University of Michigan Medical School, Ann Arbor, Michigan (J.B.B.). 5. Stanford University School of Medicine, Stanford, California (V.B.).
Abstract
BACKGROUND: Primary aldosteronism is a common cause of treatment-resistant hypertension. However, evidence from local health systems suggests low rates of testing for primary aldosteronism. OBJECTIVE: To evaluate testing rates for primary aldosteronism and evidence-based hypertension management in patients with treatment-resistant hypertension. DESIGN: Retrospective cohort study. SETTING: U.S. Veterans Health Administration. PARTICIPANTS: Veterans with apparent treatment-resistant hypertension (n = 269 010) from 2000 to 2017, defined as either 2 blood pressures (BPs) of at least 140 mm Hg (systolic) or 90 mm Hg (diastolic) at least 1 month apart during use of 3 antihypertensive agents (including a diuretic), or hypertension requiring 4 antihypertensive classes. MEASUREMENTS: Rates of primary aldosteronism testing (plasma aldosterone-renin) and the association of testing with evidence-based treatment using a mineralocorticoid receptor antagonist (MRA) and with longitudinal systolic BP. RESULTS: 4277 (1.6%) patients who were tested for primary aldosteronism were identified. An index visit with a nephrologist (hazard ratio [HR], 2.05 [95% CI, 1.66 to 2.52]) or an endocrinologist (HR, 2.48 [CI, 1.69 to 3.63]) was associated with a higher likelihood of testing compared with primary care. Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time. LIMITATIONS: Predominantly male cohort, retrospective design, susceptibility of office BPs to misclassification, and lack of confirmatory testing for primary aldosteronism. CONCLUSION: In a nationally distributed cohort of veterans with apparent treatment-resistant hypertension, testing for primary aldosteronism was rare and was associated with higher rates of evidence-based treatment with MRAs and better longitudinal BP control. The findings reinforce prior observations of low adherence to guideline-recommended practices in smaller health systems and underscore the urgent need for improved management of patients with treatment-resistant hypertension. PRIMARY FUNDING SOURCE: National Institutes of Health.
BACKGROUND: Primary aldosteronism is a common cause of treatment-resistant hypertension. However, evidence from local health systems suggests low rates of testing for primary aldosteronism. OBJECTIVE: To evaluate testing rates for primary aldosteronism and evidence-based hypertension management in patients with treatment-resistant hypertension. DESIGN: Retrospective cohort study. SETTING: U.S. Veterans Health Administration. PARTICIPANTS: Veterans with apparent treatment-resistant hypertension (n = 269 010) from 2000 to 2017, defined as either 2 blood pressures (BPs) of at least 140 mm Hg (systolic) or 90 mm Hg (diastolic) at least 1 month apart during use of 3 antihypertensive agents (including a diuretic), or hypertension requiring 4 antihypertensive classes. MEASUREMENTS: Rates of primary aldosteronism testing (plasma aldosterone-renin) and the association of testing with evidence-based treatment using a mineralocorticoid receptor antagonist (MRA) and with longitudinal systolic BP. RESULTS: 4277 (1.6%) patients who were tested for primary aldosteronism were identified. An index visit with a nephrologist (hazard ratio [HR], 2.05 [95% CI, 1.66 to 2.52]) or an endocrinologist (HR, 2.48 [CI, 1.69 to 3.63]) was associated with a higher likelihood of testing compared with primary care. Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time. LIMITATIONS: Predominantly male cohort, retrospective design, susceptibility of office BPs to misclassification, and lack of confirmatory testing for primary aldosteronism. CONCLUSION: In a nationally distributed cohort of veterans with apparent treatment-resistant hypertension, testing for primary aldosteronism was rare and was associated with higher rates of evidence-based treatment with MRAs and better longitudinal BP control. The findings reinforce prior observations of low adherence to guideline-recommended practices in smaller health systems and underscore the urgent need for improved management of patients with treatment-resistant hypertension. PRIMARY FUNDING SOURCE: National Institutes of Health.
Authors: Hude Quan; Bing Li; L Duncan Saunders; Gerry A Parsons; Carolyn I Nilsson; Arif Alibhai; William A Ghali Journal: Health Serv Res Date: 2008-08 Impact factor: 3.402
Authors: Jordana B Cohen; Michael J Lotito; Usha K Trivedi; Matthew G Denker; Debbie L Cohen; Raymond R Townsend Journal: Ann Intern Med Date: 2019-06-11 Impact factor: 25.391
Authors: Alejandro de la Sierra; Julián Segura; José R Banegas; Manuel Gorostidi; Juan J de la Cruz; Pedro Armario; Anna Oliveras; Luis M Ruilope Journal: Hypertension Date: 2011-03-28 Impact factor: 10.190
Authors: Jonathan Suarez; Jordana B Cohen; Vishnu Potluri; Wei Yang; David E Kaplan; Marina Serper; Siddharth P Shah; Peter Philip Reese Journal: J Am Soc Nephrol Date: 2018-08-17 Impact factor: 10.121
Authors: Nicolette G C van der Sande; Esther de Beus; Michiel L Bots; Michiel Voskuil; Peter J Blankestijn; Frank Visseren; Wilko Spiering Journal: J Hypertens Date: 2018-01 Impact factor: 4.844
Authors: Bryan Williams; Thomas M MacDonald; Steve V Morant; David J Webb; Peter Sever; Gordon T McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Sandosh Padmanabhan; Isla S Mackenzie; Jackie Salsbury; Morris J Brown Journal: Lancet Diabetes Endocrinol Date: 2018-04-11 Impact factor: 32.069
Authors: Leah B Rethy; Matthew J Feinstein; Chad J Achenbach; Raymond R Townsend; Adam P Bress; Sanjiv J Shah; Jordana B Cohen Journal: Hypertension Date: 2021-04-05 Impact factor: 9.897
Authors: Sasan Mirfakhraee; Maria Rodriguez; Niloofar Ganji; Richard J Auchus; Oksana Hamidi Journal: J Investig Med High Impact Case Rep Date: 2021 Jan-Dec